Ozon Pharmaceuticals Group has launched the Immunotresan drug, which combines immunomodulatory and adaptogenic properties, which makes it indispensable during the cold season and the period of increased stress. First 25,000 packages of the new drug have already been shipped to distributors.

Ozon Pharmaceuticals Group begins cooperation with the Chinese manufacturer of containers for the pharmaceutical industry Cangzhou Four Stars Glass Co. Laboratory tests have confirmed that the quality of Cangzhou Four Stars Glass products meets European standards, while the cost of materials is lower. Ozon Pharmaceuticals is now focused on studying the stabi...

Board of Directors of Ozon Pharmaceuticals recommended that dividends be paid for 6 months 2025 in the amount of ₽0.25 per ordinary share. The last day of the purchase of securities to receive dividends is October 3, 2025. Dividend yield may amount to 0.44%.

Sales of Ozon Pharmaceuticals for 6 months of 2025 amounted to 152.9 million packages of medicines, an increase of 2% compared to the previous year. In the public procurement segment, sales increased by 23% to 56.3 million packages. Retail sales decreased by 7% and amounted to 96.6 million packages.